Our results confirmed that PDIA3 is a robust prognostic biomarker for pan-cancer and predicts the immunotherapy response effectively, and it provided a main thread for further investigation on the role of PDIA3 in cancer immunity. The gene discussed is PDIA3; the disease is cancer.